Browse Newsroom

InsuLife welcomes Mr. Pål Falck and Mr. Harry J. Rodriguez to our Advisory Board

March 3, 2021

We are excited to announce that the addition of Mr. Pål Falck and Mr. Harry J. Rodriguez to our Advisory Board. Pål and Harry adds a wealth of value-adding competence to guide the company’s strategies to reach its goals.

About Harry J Rodriguez

Harry is a respected strategy-driven international finance professional with a successful track record in navigating uncertainty, identifying opportunities, and implementing effective strategies and controls in Developed and Emerging markets. He has over 30 years of leadership and C-Suite level experience in  banking, risk management, and lending covering the United States, Latin America, Asia, the Caribbean, Europe and Northern Africa. 
Harry has a Mechanical Engineering Degree from Rensselaer Polytechnic Institute (New York) and a Master of Business Administration from the Simon Business School at the University of Rochester (New York).

About Pål Falck

Pål Falck has a MBA, PhD in Clinical Nephrology focused on Pharmacokinetics. Pål Falck has a broad background within the life science sector including Nordic Medical Director in Oncology & Infections at AstraZeneca, Medical Advisor and Business Development at Pfizer Norway, Healthcare Equity Research Analyst at Arctic Securities in Norway. Pål is the Chief Business Officer at Oncorena AB and a Board Member of University of Oslo, Department of Pharmacy.

Subscribe for InsuLife News Updates
Sign up to receive the latest InsuLife news, updates and investing information delivered right to your inbox.
Newsletter Form (#1)
InsuLife is a Norwegian company aiming at bringing the unparalleled developmental INS-2301 skin-applied insulin to market.
Learn More
© Copyright 2024 - InsuLife AS, All Rights Reserved